Novel mRNA Lyme Shots Could Be Released in 2025
Two novel messenger RNA (mRNA) shots for Lyme disease currently in late-stage clinical trials could hit the market as early as 2025, Moderna announced earlier this year. Also in the race to develop the first-ever mRNA product to prevent Lyme disease are Pfizer and Austria-based Valneva, which entered into a collaborative agreement in April 2020 […]
German Report Reveals 1 in 25 Insured Individuals Treated for COVID Shot Reactions
Techniker Krankenkasse, Germany’s largest health insurance company, reported that 437,593 of 11 million (1 in 25) insured individuals in 2021 had to undergo medical treatment as a result of adverse reactions from COVID-19 shots.1 COVID shots currently approved for use in Germany include Novavax’s Nuvaxovid, Moderna’s Spikevax, Pfizer/BioNTech’s Comirnaty, Johnson & Johnson/Janssen’s Ad26.COV2.S, AstraZeneca/Oxford University’s […]
Another Shot at a Vaccine for Lyme Disease
The U.S. National Institutes of Health (NIH) has provided the University of Maryland with a $3.5 million dollar grant to develop a vaccine for Lyme disease.1 Principal investigators Utal Pal, PhD, professor at the Virginia-Maryland College of Veterinary Medicine at the University of Maryland College of Agriculture and Natural Resources and Matthias Schnell, PhD, director […]
Lyme Disease Vaccines: Past and Future
Story Highlights A new Lyme disease vaccine candidate approved by the FDA using the fast track process is currently in its second phase of clinical trials. In 1998, the FDA granted licensure for a Lyme disease vaccine called LYMErix. Following reports of severe adverse reactions to LYMErix, GlaxoSmithKline (formerly SmithKline Beecham) withdrew the vaccine from […]
